Mizuho Securities analyst Uy Ear maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of $27.00. The company's shares closed last Thursday at $15.62. According to TipRanks.com, Ear is a 2-star analyst with an average return of -0.5% and a 44.0% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Sarepta Therapeutics, and Selecta Biosciences. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $22.38 average price target, which is a 46.7% upside from current levels. In a report issued on August 1, J.P.
https://www.tipranks.com/news/blurbs/acadia-pharmaceuticals-acad-gets-a-hold-rating-from-mizuho-securities-2?utm_source=advfn.com&utm_medium=referral
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.